JP2023022224A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023022224A5 JP2023022224A5 JP2022191728A JP2022191728A JP2023022224A5 JP 2023022224 A5 JP2023022224 A5 JP 2023022224A5 JP 2022191728 A JP2022191728 A JP 2022191728A JP 2022191728 A JP2022191728 A JP 2022191728A JP 2023022224 A5 JP2023022224 A5 JP 2023022224A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024164776A JP2024178341A (ja) | 2017-05-26 | 2024-09-24 | 固定用量製剤 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511889P | 2017-05-26 | 2017-05-26 | |
| US62/511,889 | 2017-05-26 | ||
| US15/859,279 | 2017-12-29 | ||
| US15/859,279 US20180338922A1 (en) | 2017-05-26 | 2017-12-29 | Fixed dose formulations |
| JP2019565302A JP7187488B2 (ja) | 2017-05-26 | 2018-05-25 | 固定用量製剤 |
| PCT/US2018/034646 WO2018218147A1 (en) | 2017-05-26 | 2018-05-25 | Fixed dose formulations |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565302A Division JP7187488B2 (ja) | 2017-05-26 | 2018-05-25 | 固定用量製剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024164776A Division JP2024178341A (ja) | 2017-05-26 | 2024-09-24 | 固定用量製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023022224A JP2023022224A (ja) | 2023-02-14 |
| JP2023022224A5 true JP2023022224A5 (enExample) | 2023-04-10 |
| JP7561814B2 JP7561814B2 (ja) | 2024-10-04 |
Family
ID=62621055
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565302A Active JP7187488B2 (ja) | 2017-05-26 | 2018-05-25 | 固定用量製剤 |
| JP2022191728A Active JP7561814B2 (ja) | 2017-05-26 | 2022-11-30 | 固定用量製剤 |
| JP2024164776A Pending JP2024178341A (ja) | 2017-05-26 | 2024-09-24 | 固定用量製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565302A Active JP7187488B2 (ja) | 2017-05-26 | 2018-05-25 | 固定用量製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024164776A Pending JP2024178341A (ja) | 2017-05-26 | 2024-09-24 | 固定用量製剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20180338922A1 (enExample) |
| EP (1) | EP3630070A1 (enExample) |
| JP (3) | JP7187488B2 (enExample) |
| KR (3) | KR20250109242A (enExample) |
| CN (1) | CN110996914A (enExample) |
| AU (2) | AU2018272040A1 (enExample) |
| BR (1) | BR112019024747A2 (enExample) |
| CA (1) | CA3064895A1 (enExample) |
| CL (1) | CL2019003437A1 (enExample) |
| IL (2) | IL318957A (enExample) |
| MX (2) | MX2019014122A (enExample) |
| PH (1) | PH12019502782A1 (enExample) |
| TW (2) | TW202400126A (enExample) |
| UA (1) | UA126451C2 (enExample) |
| WO (1) | WO2018218147A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA42616A (fr) | 2015-03-13 | 2021-05-19 | Esperion Therapeutics Inc | Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire |
| WO2019161307A1 (en) * | 2018-02-16 | 2019-08-22 | Esperion Therapeutics, Inc. | Sustained release formulations of bempedoic acid |
| WO2020046836A1 (en) * | 2018-08-27 | 2020-03-05 | Esperion Therapeutics, Inc. | Combination drug formulations for treating patients with cardiovascular disease and associated conditions |
| EP3666750A1 (en) * | 2018-12-10 | 2020-06-17 | Sandoz AG | Crystalline form of bempedoic acid |
| WO2020213010A1 (en) * | 2019-04-16 | 2020-10-22 | Celagenex Research (India) Pvt. Ltd. | Synergistic lipid controlling compositions |
| CA3144372A1 (en) | 2019-06-21 | 2020-12-24 | Esperion Therapeutics, Inc. | Salt forms of bempedoic acid and methods for using the same |
| EP4038045A1 (en) | 2019-10-03 | 2022-08-10 | Synthon B.V. | Crystalline forms of bempedoic acid |
| WO2021110929A1 (en) | 2019-12-06 | 2021-06-10 | Synthon B.V. | Crystalline forms of sodium salt of bempedoic acid |
| WO2021205887A1 (ja) * | 2020-04-10 | 2021-10-14 | 日本酢ビ・ポバール株式会社 | 徐放性基剤 |
| WO2021220236A1 (en) * | 2020-05-01 | 2021-11-04 | Cadila Healthcare Limited | Pharmaceutical compositions for combination therapy |
| CN111559961A (zh) * | 2020-05-26 | 2020-08-21 | 杭州科巢生物科技有限公司 | 一种贝派地酸晶型及其制备方法 |
| WO2021255180A1 (en) | 2020-06-19 | 2021-12-23 | Synthon B.V. | Salts of bempedoic acid |
| US20250134841A1 (en) * | 2021-09-13 | 2025-05-01 | Synthon B.V. | Pharmaceutical composition of bempedoic acid |
| CA3256768A1 (en) | 2022-05-09 | 2023-11-16 | Renata Pharmaceutical (Ireland) Ltd | PHARMACEUTICAL COMPOSITION OF BEMPEDOIC ACID |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| ES2274013T3 (es) | 2001-01-26 | 2007-05-16 | Schering Corporation | Combinaciones de activador(es) del receptor activado por el proliferador de los peroxisomas (ppar) e inhibidor(es)m de la absorcion de estelores y tratamientos para trastornos vasculares. |
| JP4438268B2 (ja) * | 2001-03-07 | 2010-03-24 | 大日本住友製薬株式会社 | 薬物顆粒の製造方法、および薬物顆粒、ならびにそれを用いた医薬製剤 |
| US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| WO2004067489A2 (en) | 2003-01-23 | 2004-08-12 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
| NZ592194A (en) * | 2008-09-17 | 2013-04-26 | Mylan Inc | Reversed wet granulation process for preparing granulates and pharmaceutical products containing them |
| JO3239B1 (ar) * | 2008-09-22 | 2018-03-08 | Novartis Ag | تركيبات جالينية من مركبات عضوية |
| EP2168573A1 (en) * | 2008-09-30 | 2010-03-31 | LEK Pharmaceuticals D.D. | Formulations comprising ezetimibe |
| NZ595071A (en) * | 2009-03-13 | 2013-01-25 | Toyama Chemical Co Ltd | Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide |
| EP2229938B9 (en) * | 2009-03-13 | 2012-04-25 | Sanovel Ilac Sanayi ve Ticaret A.S. | Ezetimibe compositions |
| HUE038048T2 (hu) * | 2009-07-28 | 2018-09-28 | Egyt Gyogyszervegyeszeti Gyar | Új granulálási eljárás és ezzel elõállított granulátum |
| CN101926756B (zh) * | 2010-08-12 | 2012-01-18 | 北京赛科药业有限责任公司 | 一种氯吡格雷或其药学上可接受盐的固体制剂 |
| AR083417A1 (es) * | 2010-10-14 | 2013-02-21 | Novartis Ag | Composiciones farmaceuticas que contienen un dgat1 inhibidor |
| EP2468258A1 (en) * | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient |
| AR086675A1 (es) * | 2011-06-14 | 2014-01-15 | Merck Sharp & Dohme | Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina |
| WO2013023250A1 (en) * | 2011-08-16 | 2013-02-21 | Baker Idi Heart & Diabetes Institute Holdings Limited | Controlled-release formulation |
| MX378845B (es) * | 2014-01-21 | 2025-03-10 | Bpsi Holdings Llc | Revestimientos de pelicula de liberacion inmediata que contienen gliceridos de cadena media y sustratos revestidos con los mismos. |
| MA42616A (fr) * | 2015-03-13 | 2021-05-19 | Esperion Therapeutics Inc | Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire |
| MA41793A (fr) * | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| WO2017023165A1 (en) * | 2015-08-04 | 2017-02-09 | Dezima Pharma B.V. | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator |
| JP2018536710A (ja) * | 2015-11-06 | 2018-12-13 | ジェンファイア・セラピューティクス・インコーポレイテッドＧｅｍｐｈｉｒｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 混合型脂質異常症の治療 |
-
2017
- 2017-12-29 US US15/859,279 patent/US20180338922A1/en not_active Abandoned
-
2018
- 2018-05-25 EP EP18731684.9A patent/EP3630070A1/en active Pending
- 2018-05-25 TW TW112108490A patent/TW202400126A/zh unknown
- 2018-05-25 CN CN201880049937.4A patent/CN110996914A/zh active Pending
- 2018-05-25 TW TW107118013A patent/TWI798228B/zh active
- 2018-05-25 UA UAA201911462A patent/UA126451C2/uk unknown
- 2018-05-25 AU AU2018272040A patent/AU2018272040A1/en not_active Abandoned
- 2018-05-25 PH PH1/2019/502782A patent/PH12019502782A1/en unknown
- 2018-05-25 KR KR1020257022127A patent/KR20250109242A/ko active Pending
- 2018-05-25 WO PCT/US2018/034646 patent/WO2018218147A1/en not_active Ceased
- 2018-05-25 IL IL318957A patent/IL318957A/en unknown
- 2018-05-25 MX MX2019014122A patent/MX2019014122A/es unknown
- 2018-05-25 IL IL270866A patent/IL270866B2/en unknown
- 2018-05-25 KR KR1020197038244A patent/KR102698987B1/ko active Active
- 2018-05-25 BR BR112019024747A patent/BR112019024747A2/pt unknown
- 2018-05-25 CA CA3064895A patent/CA3064895A1/en active Pending
- 2018-05-25 KR KR1020247028001A patent/KR102830720B1/ko active Active
- 2018-05-25 JP JP2019565302A patent/JP7187488B2/ja active Active
-
2019
- 2019-11-25 CL CL2019003437A patent/CL2019003437A1/es unknown
- 2019-11-26 MX MX2023006541A patent/MX2023006541A/es unknown
-
2022
- 2022-04-14 US US17/720,625 patent/US20220249380A1/en active Pending
- 2022-11-30 JP JP2022191728A patent/JP7561814B2/ja active Active
-
2024
- 2024-06-26 AU AU2024204369A patent/AU2024204369B2/en active Active
- 2024-09-24 JP JP2024164776A patent/JP2024178341A/ja active Pending